Delivering COVID-19 vaccine trials at speed: the implementation of a phase IV UK multi-centre randomised controlled trial to determine safety and immunogenicity of COVID-19 vaccines co-administered with seasonal influenza vaccines (ComFluCOV)

被引：0
|
作者：
Sarah Baos
Rachel Todd
Russell Thirard
Rosie Harris
Jana Kirwan
Katherine Joyce
David Hutton
Adam Finn
Madeleine Clout
Heike Cappel-Porter
Chris A Rogers
Rajeka Lazarus
Lucy Culliford
机构：
[1] University of Bristol,Bristol Trials Centre
[2] University of Bristol,Bristol Vaccine Centre, Schools of Population Health Sciences and of Cellular and Molecular Medicine
[3] University Hospitals Bristol and Weston NHS Foundation Trust,undefined
来源：
Trials | / 25卷
关键词：
COVID-19 vaccine; Influenza vaccine; Randomised controlled trial (RCT); Efficient delivery; Urgent Public Health (UPH);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Delivering COVID-19 vaccine trials at speed: the implementation of a phase IV UK multi-centre randomised controlled trial to determine safety and immunogenicity of COVID-19 vaccines co-administered with seasonal influenza vaccines (ComFluCOV)
    Baos, Sarah
    Todd, Rachel
    Thirard, Russell
    Harris, Rosie
    Kirwan, Jana
    Joyce, Katherine
    Hutton, David
    Finn, Adam
    Clout, Madeleine
    Cappel-Porter, Heike
    Rogers, Chris A.
    Lazarus, Rajeka
    Culliford, Lucy
    TRIALS, 2024, 25 (01)
  • [2] Comparison of assays used to detect antibody response in COVID-19 vaccine trials: Results from of a UK multi-Centre randomised controlled trial to determine the immunogenicity responses of COVID-19 vaccines administered concomitantly with seasonal influenza vaccines (ComFluCOV)
    Lazarus, Rajeka
    Harris, Rosie
    Thirard, Russell
    Baos, Sarah
    Culliford, Lucy
    Todd, Rachel
    Hallis, Bassam
    Charlton, Sue
    Finn, Adam
    Snape, Matthew D.
    Rogers, Chris A.
    VACCINE, 2024, 42 (26)
  • [3] Safety of co-administered mRNA COVID-19 and influenza vaccines
    Reactions Weekly, 2023, 1941 (1) : 12 - 12
  • [4] Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial
    Lazarus, Rajeka
    Baos, Sarah
    Cappel-Porter, Heike
    Carson-Stevens, Andrew
    Clout, Madeleine
    Culliford, Lucy
    Emmett, Stevan R.
    Garstang, Jonathan
    Gbadamoshi, Lukuman
    Hallis, Bassam
    Harris, Rosie A.
    Hutton, David
    Jacobsen, Nick
    Joyce, Katherine
    Kaminski, Rachel
    Libri, Vincenzo
    Middleditch, Alex
    McCullagh, Liz
    Moran, Ed
    Phillipson, Adrian
    Price, Elizabeth
    Ryan, John
    Thirard, Russell
    Todd, Rachel
    Snape, Matthew D.
    Tucker, David
    Williams, Rachel Lauren
    Nguyen-Van-Tam, Jonathan S.
    Finn, Adam
    Rogers, Chris A.
    LANCET, 2021, 398 (10318): : 2277 - 2287
  • [5] Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial
    Toback, Seth
    Galiza, Eva
    Cosgrove, Catherine
    Galloway, James
    Goodman, Anna L.
    Swift, Pauline A.
    Rajaram, Sankarasubramanian
    Graves-Jones, Alison
    Edelman, Jonathan
    Burns, Fiona
    Minassian, Angela M.
    Cho, Iksung
    Kumar, Lakshmi
    Plested, Joyce S.
    Rivers, E. Joy
    Robertson, Andreana
    Dubovsky, Filip
    Glenn, Greg
    Heath, Paul T.
    LANCET RESPIRATORY MEDICINE, 2022, 10 (02): : 167 - 179
  • [6] A single blinded, phase IV, adaptive randomised control trial to evaluate the safety of coadministration of seasonal influenza and COVID-19 vaccines (The FluVID study)
    Ramsay, J. A.
    Jones, M.
    Vande More, A. M.
    Hunt, S. L.
    Williams, P. C. M.
    Messer, M.
    Wood, N.
    Macartney, K.
    Lee, F. J.
    Britton, W. J.
    Snelling, T. L.
    Caterson, I. D.
    VACCINE, 2023, 41 (48) : 7250 - 7258
  • [7] Immunogenicity and safety of an inactivated COVID-19 vaccine (CoronaVac®) co-administered with an inactivated enterovirus type 71 vaccine (Inlive®): A phase 4, randomized, controlled trial
    Shu, Yajun
    Sun, Zhuoqun
    Gao, Fan
    Huang, Zhuhang
    Meng, Xing
    Chen, Shaomin
    Shu, Qun
    Wang, Lianhao
    Zhang, Hengming
    Ying, Zhifang
    Zhang, Jikai
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [8] How the adverse effect counting window affected vaccine safety calculations in randomised trials of COVID-19 vaccines
    Lataster, Raphael
    JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2024, 30 (03) : 453 - 458
  • [9] Re: How the adverse effect counting window affected vaccine safety calculations in randomised trials of COVID-19 vaccines
    Daungsupawong, Hinpetch
    Wiwanitkit, Viroj
    JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2024, 30 (04) : 584 - 584
  • [10] No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: A randomized trial
    Naficy, Abdi
    Kuxhausen, Adrienne
    Seifert, Harry
    Hastie, Andrew
    Leav, Brett
    Miller, Jacqueline
    Anteyi, Kate
    Mwakingwe-Omari, Agnes
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
12345